Salivary transcriptomic and microbial biomarkers for pancreatic cancer
View Patent ↗The present invention relates to the identification of pancreatic cancer biomarkers for the detection of early pancreatic cancer. The present invention also provides methods of diagnosing pancreatic cancer and distinguishing between pancreatic cancer and chronic pancreatitis. The present invention additionally provides kits that find use in the practice of the methods of the invention.
1. A method for distinguishing subjects with pancreatic cancer from those without pancreatic cancer, the method comprising:
a) analyzing a saliva sample from a test subject with an assay that specifically detects at least four nucleic acid or polypeptide markers in the saliva sample, wherein at least four biomarkers are selected from the group consisting of MBD3L2, KRAS, ACRV1, CDKL3, and DPM1,
b) detecting a change in the level of the at least four biomarkers selected from the group consisting of an increase in the level of MBD3L2, an increase in the level of KRAS, an increase in the level of ACRV1, a decrease in the level of CDKL3 and a decrease in the level of DPM1 relative to a control, thereby
c) detecting the presence of pancreatic cancer in the test subject, and effectuating a pancreatic cancer treatment regimen on the test subject.
2. The method of claim 1 , wherein the combination of markers is KRAS, MBD3L2, ACRV1, and DPM1, and wherein higher levels of KRAS, MBD3L2, and ACRV1, and a lower level of DPM1 relative to a control distinguishes the test subject from those subjects without pancreatic cancer and all of these markers are detected.
3. The method of claim 1 , wherein those subjects with pancreatic cancer are distinguished from those subjects without pancreatic cancer but with chronic pancreatitis, the method comprising detecting a level of a combination of markers wherein the markers are MBD3L2, KRAS, STIM2, ACRV1, DMD, CABLES1, TK2, GLTSCR2, and CDKL3.
4. The method of claim 1 , wherein the combination of markers is KRAS, MBD3L2 ACRV1 and CDKL3 and wherein higher levels of KRAS ACRV1 and MBD3L2 and a lower level of CDKL3 relative to a control distinguishes the test subject from those subjects without pancreatic cancer and all of these markers are detected.
5. The method of claim 4 , further comprising the detection of at least one additional biomarker selected from the group consisting of STIM2, DMD, CABLES1, TK2, GLTSCR2 and DPM1.
6. A method comprising the steps of: obtaining a saliva sample from a test subject, detecting in the saliva sample a change in the level of at least four nucleic acid or polypeptide markers selected from the group consisting of an increase in the level of MBD3L2, an increase in the level of KRAS, an increase in the level of ACRV1, a decrease in the level of CDKL3, and a decrease in the level of DPM1 relative to a control, thereby detecting the presence of pancreatic cancer in the test subject, and effectuating a pancreatic cancer treatment regimen on the test subject.
7. A method of treating pancreatic cancer comprising administering a pancreatic cancer treatment regimen to a subject who has been identified as having a change in the level of at least four nucleic acid or polypeptide markers in a saliva sample of the subject, wherein the change in the level of at least four nucleic acid or polypeptide markers are selected from the group consisting of an increase in the level of MBD3L2, an increase in the level of KRAS, an increase in the level of ACRV1, a decrease in the level of CDKL3, and a decrease in the level of DPM1 relative to a control.